Tourmaline Bio (TRML) News Today $12.21 -0.16 (-1.29%) Closing price 04:00 PM EasternExtended Trading$12.23 +0.02 (+0.16%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Tourmaline Bio management to meet with TruistFebruary 19 at 8:20 PM | msn.comTourmaline Bio, Inc. (NASDAQ:TRML) Given Average Rating of "Buy" by AnalystsFebruary 19 at 2:21 AM | americanbankingnews.comTourmaline Bio, Inc. (NASDAQ:TRML) Given Average Recommendation of "Buy" by AnalystsShares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have been assigned an average recommendation of "Buy" from the six ratings firms that are currently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-monFebruary 19 at 2:20 AM | marketbeat.comHead-To-Head Contrast: Tourmaline Bio (NASDAQ:TRML) and Passage Bio (NASDAQ:PASG)February 18 at 2:47 AM | americanbankingnews.comTourmaline Bio, Inc. (NASDAQ:TRML) Sees Large Growth in Short InterestTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,710,000 shares, an increase of 16.3% from the January 15th total of 2,330,000 shares. Based on an average trading volume of 248,100 shares, the days-to-cover ratio is currently 10.9 days. Currently, 17.4% of the shares of the stock are sold short.February 16, 2025 | marketbeat.comLeerink Partnrs Raises Earnings Estimates for Tourmaline BioTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at Leerink Partnrs raised their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($2.83February 10, 2025 | marketbeat.comLeerink Partnrs Comments on Tourmaline Bio FY2029 EarningsTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of Tourmaline Bio in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company willFebruary 7, 2025 | marketbeat.comJennison Associates LLC Has $17.15 Million Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)Jennison Associates LLC lessened its position in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 26.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 845,800 shares of the company's stock after selling 306,1February 6, 2025 | marketbeat.comTourmaline Bio management to meet with Cantor FitzgeraldFebruary 5, 2025 | markets.businessinsider.comTourmaline Bio, Inc. (NASDAQ:TRML) Short Interest UpdateTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 2,080,000 shares, an increase of 26.8% from the December 31st total of 1,640,000 shares. Approximately 13.8% of the shares of the company are sold short. Based on an average trading volume of 197,500 shares, the days-to-cover ratio is presently 10.5 days.January 31, 2025 | marketbeat.comTourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech ConferenceJanuary 27, 2025 | markets.businessinsider.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of "Buy" from BrokeragesTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six analysts that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among analysts thatJanuary 25, 2025 | marketbeat.comCantor Fitzgerald Comments on Tourmaline Bio FY2025 EarningsTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Tourmaline Bio in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn (January 22, 2025 | marketbeat.comShort Interest in Tourmaline Bio, Inc. (NASDAQ:TRML) Rises By 26.8%Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,080,000 shares, an increase of 26.8% from the December 15th total of 1,640,000 shares. Based on an average trading volume of 197,500 shares, the short-interest ratio is currently 10.5 days. Currently, 13.8% of the shares of the company are short sold.January 16, 2025 | marketbeat.comBarclays PLC Has $819,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML)Barclays PLC raised its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 283.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,833 shares of the company's stock after purchasingJanuary 16, 2025 | marketbeat.comTourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. RidkerJanuary 10, 2025 | globenewswire.comTourmaline Bio: Promising Cardiovascular and Innovative Indications Drive Buy Rating Amid Upcoming Data MilestonesJanuary 8, 2025 | markets.businessinsider.comTourmaline Bio, Inc. (NASDAQ:TRML) Position Lifted by Geode Capital Management LLCGeode Capital Management LLC grew its stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 6.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 482,078 shares of the comJanuary 1, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Rating of "Buy" by AnalystsTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) has been given a consensus rating of "Buy" by the six ratings firms that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objectDecember 31, 2024 | marketbeat.comState Street Corp Has $10.59 Million Stake in Tourmaline Bio, Inc. (NASDAQ:TRML)State Street Corp lifted its holdings in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 25.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 411,980 shares of the company's stock after acquirDecember 27, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Shares Down 3.9% - Should You Sell?Tourmaline Bio (NASDAQ:TRML) Shares Down 3.9% - Should You Sell?December 24, 2024 | marketbeat.comFmr LLC Has $387,000 Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)Fmr LLC decreased its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 93.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,063 shares of the company's stock afterDecember 20, 2024 | marketbeat.comWellington Management Group LLP Raises Stake in Tourmaline Bio, Inc. (NASDAQ:TRML)Wellington Management Group LLP raised its stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 72.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 65,741 shares of the company's stock aftDecember 19, 2024 | marketbeat.comFY2025 EPS Estimate for Tourmaline Bio Increased by AnalystTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Research analysts at Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for shares of Tourmaline Bio in a research report issued on Wednesday, December 11th. Leerink Partnrs analyst T. Smith now forecasts that the company wilDecember 13, 2024 | marketbeat.comStrategic Developments in Tourmaline Bio’s Cardiovascular Programs Drive Buy RatingDecember 11, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Tourmaline Bio (NASDAQ:TRML)HC Wainwright reissued a "buy" rating and issued a $49.00 target price on shares of Tourmaline Bio in a research note on Wednesday.December 11, 2024 | marketbeat.comTourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor DayDecember 10, 2024 | globenewswire.com338,437 Shares in Tourmaline Bio, Inc. (NASDAQ:TRML) Purchased by Point72 Asset Management L.P.Point72 Asset Management L.P. acquired a new position in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 338,437 shares of the company's stock, valued at approximately $8,701,000. PoDecember 8, 2024 | marketbeat.comBMO Capital Initiates Coverage of Tourmaline Bio (TRML) with Outperform RecommendationDecember 6, 2024 | msn.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of "Buy" from BrokeragesShares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have received an average recommendation of "Buy" from the six brokerages that are currently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has issued a strongDecember 6, 2024 | marketbeat.comBMO Capital Markets Initiates Coverage on Tourmaline Bio (NASDAQ:TRML)BMO Capital Markets started coverage on shares of Tourmaline Bio in a report on Friday. They issued an "outperform" rating and a $50.00 target price on the stock.December 6, 2024 | marketbeat.comAcuta Capital Partners LLC Has $8.54 Million Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)Acuta Capital Partners LLC raised its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 23.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 332,095 shares of the company's stockNovember 28, 2024 | marketbeat.comJennison Associates LLC Increases Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML)Jennison Associates LLC raised its position in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 2.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,151,973 shares of the company's stock after purcNovember 22, 2024 | marketbeat.comTourmaline Bio FY2024 EPS Forecast Lowered by HC WainwrightTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - HC Wainwright decreased their FY2024 earnings per share estimates for shares of Tourmaline Bio in a research note issued to investors on Monday, November 11th. HC Wainwright analyst Y. Chen now expects that the company will earn ($2.85) per shareNovember 14, 2024 | marketbeat.comTourmaline Bio to Host Investor Day on Tuesday, December 10, 2024November 14, 2024 | globenewswire.comTourmaline Bio price target raised to $49 from $48 at H.C. WainwrightNovember 12, 2024 | markets.businessinsider.comTourmaline Bio, Inc. Reports Third Quarter Financial ResultsNovember 11, 2024 | tipranks.comTourmaline Bio (NASDAQ:TRML) Price Target Raised to $49.00 at HC WainwrightHC Wainwright increased their price objective on Tourmaline Bio from $48.00 to $49.00 and gave the stock a "buy" rating in a research note on Monday.November 11, 2024 | marketbeat.comTourmaline Bio’s Promising Clinical Developments and Financial Stability Underpin Buy RatingNovember 11, 2024 | markets.businessinsider.comTourmaline Bio files $350M mixed securities shelfNovember 9, 2024 | markets.businessinsider.comTourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 7, 2024 | globenewswire.comAlphaCentric Advisors LLC Sells 69,500 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)AlphaCentric Advisors LLC reduced its position in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 92.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,500 shares of the company's stock after selling 69,500 shares during the peNovember 5, 2024 | marketbeat.comTourmaline Bio: Unlocking Value through Promising IL-6 Inhibition Strategy in ASCVD TreatmentNovember 5, 2024 | markets.businessinsider.comTourmaline Bio to Present at Upcoming Investor ConferencesOctober 31, 2024 | globenewswire.comTourmaline Bio, Inc. (NASDAQ:TRML) Short Interest Down 20.0% in OctoberTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) was the recipient of a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 1,520,000 shares, a decrease of 20.0% from the September 30th total of 1,900,000 shares. Currently, 10.2% of the company's stock are short sold. Based on an average daily volume of 202,700 shares, the short-interest ratio is presently 7.5 days.October 27, 2024 | marketbeat.comTruist Financial Sticks to Its Buy Rating for Tourmaline Bio (TRML)October 25, 2024 | markets.businessinsider.comTourmaline Bio (NASDAQ:TRML) Stock Quotes, Forecast and News SummaryOctober 24, 2024 | benzinga.comGet Your First Look at Tourmaline’s Definitive Marsha P. Johnson BiographyOctober 23, 2024 | msn.comPiper Sandler Sticks to Its Buy Rating for Tourmaline Bio (TRML)October 17, 2024 | markets.businessinsider.comTourmaline Bio, Inc. to Post FY2024 Earnings of ($2.85) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:TRML)Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research report issued on Tuesday, October 15th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of ($2.85)October 17, 2024 | marketbeat.com Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address TRML Media Mentions By Week TRML Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRML News Sentiment▼0.590.60▲Average Medical News Sentiment TRML News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRML Articles This Week▼52▲TRML Articles Average Week Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dyne Therapeutics News Structure Therapeutics News Ardelyx News Indivior News Nurix Therapeutics News Vir Biotechnology News Syndax Pharmaceuticals News Arvinas News ANI Pharmaceuticals News Day One Biopharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRML) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRML Stock Alerts